Gropivirin 500mg 20 tablets — Made in Ukraine — Free Delivery

Pharmacological properties

Pharmacodynamics. Gropivirin is an antiviral agent with immunomodulatory properties. the preparation eliminates the deficiency or normalizes (individual) dysfunction of cellular immunity, inducing maturation and differentiation of T-lymphocytes and T1-helpers, potentiating the induction of a lymphoproliferative response in mitogenic or antigen-active cells. Gropivirin simulates the cytotoxicity of t-lymphocytes and natural killer cells, the function of t8-suppressors) and t4-helpers), and also increases the amount of igg and complement surface markers. Gropivirin increases the synthesis of interleukin (il) -1 and the synthesis of il-2, regulates the expression of il-2 receptors. Gropivirin significantly increases the secretion of endogenous γ-interferon and reduces the production of il-4 in the body. Gropivirin enhances the action of neutrophilic granulocytes, chemotaxis and phagocytosis of monocytes and macrophages. Gropivirin inhibits the synthesis of the virus by incorporating inosine-orotic acid into the polyribosomes of the cell affected by the virus and inhibits the attachment of adenylic acid to the viral irna.

Pharmacokinetics. After taking the preparation orally at a dose of 1.5 g, Cmax of inosine pranobex in blood plasma is reached after 1 hour and is 600 μg / ml. In the body of inosine, pranobex is metabolized in the liver to form uric acid. T1 / 2 of 4- (acetylamino) benzoate is 50 minutes, 1- (dimethylamino) -2-propanol - 3.5 hours. It is excreted in the urine as metabolites.

Indications

Viral infections caused by herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-barr virus, measles virus, mumps virus, including in patients with immunodeficiency states; viral respiratory infections; papillomavirus infections of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy); acute viral encephalitis (as part of complex therapy); viral hepatitis (as part of complex therapy); subacute sclerosing panencephalitis (as part of complex therapy).

Application

The preparation is administered orally.

The daily dose depends on body weight, course and severity of the disease, the patient's condition.

Adults and children over the age of 12 years: 50 mg / kg body weight (usually 6-8 tablets, distributed over 3-4 doses), the maximum daily dose is 4 g.

Children aged 1 to 12 years: 50 mg / kg (usually 1 tablet per 10 kg of body weight for a child weighing 10-20 kg, with a body weight of 20 kg, prescribe a dose as for adults) for 3-4 doses per day, the maximum daily dose is 4 g. To facilitate swallowing, the tablet can be crushed.

Duration of treatment

Acute diseases: for diseases with a short-term course of treatment is from 5 to 14 days. After a decrease in the severity of symptoms of the disease, treatment should be continued for another 1-2 days or longer, depending on the course of the disease, the patient's condition.

Long-term viral diseases: treatment should be continued for 1–2 weeks after the severity of symptoms of the disease decreases or longer, depending on the course of the disease, the patient's condition.

Recurrent diseases: At the initial stage of treatment, the same recommendations apply as for acute diseases. During maintenance therapy, the dose can be reduced to 500-1000 mg (1-2 tablets) per day. When the first signs of relapse appear, it is necessary to resume taking the daily dose recommended for acute diseases, and you should continue taking this dose for 1-2 days after the symptoms disappear. The course of treatment can be repeated several times on the recommendation of a doctor, depending on the patient's condition.

For chronic diseases, the preparation is used in a daily dose of 50 mg / kg in accordance with the following schemes:

asymptomatic diseases - take within 30 days with a break of 60 days;

diseases with moderately severe symptoms - take within 60 days with a break of 30 days;

diseases with severe symptoms - apply for 90 days with a break of 30 days.

The course of treatment should be repeated as many times as necessary, while it is necessary to constantly monitor the patient's health status and indications for prolonging therapy.

For infections caused by the human papillomavirus (external genital warts (genital warts) or papillomavirus infection of the cervical canal), take 3 g (2 tablets 3 times a day) for 14-28 days as monotherapy or as an adjunct to local therapy or surgical treatment in accordance with the following schemes:

for the treatment of low-risk patients (patients with normal immunity or patients with a low risk of relapse), the preparation is used for 14-28 days until the maximum eradication of the virus is achieved, then a break for 2 months should be taken. The course of treatment can be repeated using the same dose, while constant monitoring of the patient's condition and indications for prolongation of therapy is necessary;

for the treatment of high-risk patients * (patients with immunodeficiency or with a high risk of relapse), the preparation is used 5 days a week, consecutively 1-2 weeks a month for 3 months. The course of treatment should be repeated as many times as necessary, while it is necessary to constantly monitor the patient's health status and indications for prolonging therapy.

* High-risk factors in patients with recurrent or cervical dysplasia, or papillomavirus infection of the genitals, as in other similar diseases, include:

immunodeficiency caused by:

- a history of chronic or recurrent infections or sexually transmitted diseases;

- chemotherapy;

- chronic alcoholism;

• long-term use of oral contraceptives (≥2 years);
• the level of folate in erythrocytes is 660 nmol / l;
• having multiple sexual partners or replacing a permanent sexual partner;
• frequent vaginal intercourse (≥2–6 times a week) or anal sex;
• atopy (hereditary predisposition to hypersensitivity);
• poorly controlled diabetes;
• smoking;
• papillomavirus infection of the genitals that lasts 2 years or has ≥3 recurrences in history;
• the patient has skin warts in childhood.

In subacute sclerosing panencephalitis, the daily dose is 100 mg / kg, the maximum dose is 3-4 g / day, while it is necessary to constantly monitor the patient's health status and indications for prolongation of therapy.

Contraindications

Hypersensitivity to any component of the preparation, gout, hyperuricemia.

Side effects

A temporary increase in the level of uric acid in the blood plasma in the urine, which will normalize a few days after the end of treatment.

Laboratory tests: an increase in the level of uric acid in the blood, an increase in the level of uric acid in the urine, an increase in the level of urea nitrogen in the blood, an increase in the level of ALT and AST, an increase in the level of alkaline phosphatase in the blood.

General disorders: fatigue, malaise.

On the part of the skin and subcutaneous tissue: rash, itching.

On the part of the digestive tract: nausea, vomiting, discomfort in the epigastric region of the abdomen, diarrhea, constipation.

From the nervous system: headache, dizziness, drowsiness, sleep disturbance.

From the musculoskeletal system and muscles: arthralgia.

Mental disorders: nervousness.

From the urinary system: polyuria.

Other adverse reactions have also been reported:

from the digestive tract: abdominal pain (in the upper part);

from the immune system: anaphylactic reactions, anaphylactic shock, angioedema, hypersensitivity, urticaria;

from the nervous system: dizziness;

on the part of the skin and subcutaneous tissue: erythema.

Special instructions

It should be used in patients with urolithiasis and with reduced function on the scale so that during treatment with gropivirin , a temporary increase in the level of uric acid in the blood plasma is possible, especially in men and the elderly. when using the preparation, the 3-month system monthly check the laboratory indicators of liver and kidney function (transaminases, creatinine), the level of uric acid in the plasma, and conduct a blood test.

Some individuals may experience acute hypersensitivity reactions (angioedema, anaphylactic shock, urticaria). In this case, therapy with Gropivirin should be discontinued.

With prolonged use of the preparation, there is a risk of developing nephrolithiasis.

Application during pregnancy or lactation. Investigation of the potential for fetal abnormalities and malfunctioning in humans. It is not known whether inosine pranobex passes into breast milk. It is not recommended to use the preparation during pregnancy and lactation.

Children. The preparation is used in children aged 1 year and older.

The ability to influence the reaction rate when driving or working with other mechanisms. The effects on the reaction rate when driving or operating other mechanisms have not been investigated. The preparation may cause dizziness or other side reactions from the nervous system.

Interactions

The preparation should not be taken concurrently with immunosuppressants. caution is required to prescribe a preparation with xanthine oxidase inhibitors or agents that promote the excretion of uric acid, including diuretics - thiazide diuretics (such as hydrochlorothiazide, chlorthalidone, indapamide) and loop diuretics (for example furosemide, torasemide, ethacrynic acid).

With simultaneous use with azidothymidine, nucleotide formation increases due to an increase in the bioavailability of azidothymidine in blood plasma and an increase in intracellular phosphorylation in human blood monocytes.

Overdose

Overdose cases were not observed. overdose can cause an increase in the level of uric acid in the blood plasma and urine. symptomatic treatment.

Storage conditions

In its original packaging at a temperature not exceeding 25 ° C.